(Image: https://images20.fotki.com/v113/photos/2/3651632/13703394/Xareltolawsuit220615-vi.jpg)Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical organizations, including the makers of Xarelto, possess a duty to make sure that their drugs are reasonably secure for use - and failure to complete so could be grounds for compensation. Our lawyers are operating challenging to acquire those hurt by the drug the compensation they are entitled to.

Whilst bleeding is really a common complication linked with anticoagulants, it has been alleged that Xarelto is far more hazardous than traditional blood thinners since no antidote exists to reverse its blood-thinning effects. This means that, in the event of an emergency, patients may be at threat for irreversible bleeding difficulties, which includes life-threatening internal and gastrointestinal hemorrhaging.

In case you or possibly a loved one suffered a severe bleeding event right after taking Xarelto, you may have legal recourse. For more data, contact us today to have your case reviewed, totally free of charge.
Compensation Possibilities

xarelto-compensation-photoThe plaintiffs in these lawsuits are in search of compensation from Bayer and Janssen for past and future healthcare bills, lost wages, pain and suffering and, in cases of death, funeral expenditures. Furthermore, they're seeking punitive damages, which are normally awarded to punish click the up coming web site defendant and deter other organizations from acting similarly.
Why Are Lawsuits Being Filed?

Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective implies of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs within the lawsuits allege critical and fatal injuries, such as cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.

In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:

The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.

Visit this page for more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set

The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.

Discussion

Enter your comment (wiki syntax is allowed):

Personal Tools